Author:
Hack C.C.,Häberle L.,Brucker S.Y.,Janni W.,Volz B.,Loehberg C.R.,Hartkopf A.D.,Walter C.-B.,Baake G.,Fridman A.,Malter W.,Wuerstlein R.,Harbeck N.,Hoffmann O.,Kuemmel S.,Martin B.,Thomssen C.,Graf H.,Wolf C.,Lux M.P.,Bayer C.M.,Rauh C.,Almstedt K.,Gass P.,Heindl F.,Brodkorb T.,Willer L.,Lindner C.,Kolberg H.-C.,Krabisch P.,Weigel M.,Steinfeld-Birg D.,Kohls A.,Brucker C.,Schulz V.,Fischer G.,Pelzer V.,Rack B.,Beckmann M.W.,Fehm T.,Rody A.,Maass N.,Hein A.,Fasching P.A.,Nabieva N.
Reference46 articles.
1. The German Guideline Programme in Oncology (German Cancer Society, German Cancer Aid, AWMF). S3-Guideline on Diagnostics, Therapy and Follow-up of Breast Cancer, long version 4.0 (2017), AWMF registration number: 032–045OL, http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom.
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer (version 4.2017). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Accessed on February 13, 2017).
3. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials;Early Breast Cancer Trialists’ Collaborative G;Lancet,2015
4. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer;Breast International Group 1-98 Collaborative Group;N Engl J Med,2005
5. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial;Baum;Lancet,2002